11/20/2015 - 12:10pm

Alchemia’s shareholders approved the sale of Fondaparinux at the company’s annual general meeting held on Nov. 10.

11/20/2015 - 11:57am

The Food and Drug Administration on Monday issued new warning labeling guidance for medicines containing acetaminophen, according to a blog posted by the Regulatory Affairs Professionals Society. "The guidance ... helps to clarify certain cases where manufacturers of internal analgesic, antipyretic and antirheumatic OTC drugs would be able to change liver warnings when the product's directions for use result in a maximum daily dose of acetaminophen that is less than 4,000 mg for adults," wrote Zachary Brennan. (RAPS


11/20/2015 - 11:11am

The 2016 CEI rated 851 businesses in the report, which evaluates LGBT-related policies and practices.

11/20/2015 - 10:50am

GNC pulls USPlabs products off shelves following Department of Justice action taken Wednesday. 

11/20/2015 - 10:31am

Mylan's acquisition of Jai Pharma brings Mylan a broad women's care portfolio, strong technical capabilities and dedicated hormone manufacturing. 

11/20/2015 - 10:10am

Walmart on Friday named George Riedl as SVP, president Walmart Health and Wellness, reporting to Michelle Gloeckler, Walmart EVP consumables and health and wellness.

11/20/2015 - 9:50am

With the U.S. Treasury announcing plans to crack down on tax-inversion deals on Thursday, pharmaceutical giants Pfizer and Allergen have accelerated their merger talks, according to reports. The potential $150 billion deal could see Pfizer redomicile in Ireland. (Reuters)

11/20/2015 - 9:29am

The average annual cost of a specialty medication used on a chronic basis exceeded $53,000 in 2013, which is more than the median U.S. household income, AARP noted. 

11/19/2015 - 4:15pm

With the 17th Annual NACDS Foundation Dinner rapidly approaching, the publicity surrounding the 2015 Get Smart About Antibiotics Week provides a timely demonstration of the public health relevance that the NACDS Foundation's benefactors will support on Dec. 3.